61 related articles for article (PubMed ID: 26847682)
1. Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo.
Yoo JY; Swanner J; Otani Y; Nair M; Park F; Banasavadi-Siddegowda Y; Liu J; Jaime-Ramirez AC; Hong B; Geng F; Guo D; Bystry D; Phelphs M; Quadri H; Lee TJ; Kaur B
Neuro Oncol; 2019 Sep; 21(9):1131-1140. PubMed ID: 31063549
[TBL] [Abstract][Full Text] [Related]
2. Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma.
Grbovic-Huezo O; Pitter KL; Lecomte N; Saglimbeni J; Askan G; Holm M; Melchor JP; Chandwani R; Joshi S; Haglund C; Iacobuzio-Donahue CA; Chiosis G; Tammela T; Leach SD
Proc Natl Acad Sci U S A; 2020 Dec; 117(48):30670-30678. PubMed ID: 33199632
[TBL] [Abstract][Full Text] [Related]
3. Combined PI3K and MAPK inhibition synergizes to suppress PDAC.
Bye BA; Jack J; Pierce A; Walsh RM; Eades A; Chalise P; Olou A; VanSaun MN
bioRxiv; 2023 Aug; ():. PubMed ID: 37645960
[TBL] [Abstract][Full Text] [Related]
4. Metastatic progression is associated with dynamic changes in the local microenvironment.
Aiello NM; Bajor DL; Norgard RJ; Sahmoud A; Bhagwat N; Pham MN; Cornish TC; Iacobuzio-Donahue CA; Vonderheide RH; Stanger BZ
Nat Commun; 2016 Sep; 7():12819. PubMed ID: 27628423
[TBL] [Abstract][Full Text] [Related]
5. Kupffer cells prevent pancreatic ductal adenocarcinoma metastasis to the liver in mice.
Thomas SK; Wattenberg MM; Choi-Bose S; Uhlik M; Harrison B; Coho H; Cassella CR; Stone ML; Patel D; Markowitz K; Delman D; Chisamore M; Drees J; Bose N; Beatty GL
Nat Commun; 2023 Oct; 14(1):6330. PubMed ID: 37816712
[TBL] [Abstract][Full Text] [Related]
6. DON of Hope: Starving Pancreatic Cancer by Glutamine Antagonism.
Pillai R; Papagiannakopoulous T
Cancer Res; 2024 Feb; 84(3):349-350. PubMed ID: 38117482
[TBL] [Abstract][Full Text] [Related]
7. Targeting the IκB Kinase Enhancer and Its Feedback Circuit in Pancreatic Cancer.
Challa S; Husain K; Kim R; Coppola D; Batra SK; Cheng JQ; Malafa MP
Transl Oncol; 2020 Feb; 13(2):481-489. PubMed ID: 32004866
[TBL] [Abstract][Full Text] [Related]
8. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.
Shingu T; Holmes L; Henry V; Wang Q; Latha K; Gururaj AE; Gibson LA; Doucette T; Lang FF; Rao G; Yuan L; Sulman EP; Farrell NP; Priebe W; Hess KR; Wang YA; Hu J; Bögler O
J Transl Med; 2016 Feb; 14():46. PubMed ID: 26861698
[TBL] [Abstract][Full Text] [Related]
9. Newly developed preclinical models reveal broad-spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide.
Matsuoka T; Sugiyama A; Miyawaki Y; Hidaka Y; Okuno Y; Sakai H; Tanaka H; Yoshikawa K; Fukui T; Mizuno K; Sumiyoshi T; Goto T; Inoue T; Akamatsu S; Kobayashi T; Nakamura E
Cancer Sci; 2024 Jan; 115(1):283-297. PubMed ID: 37923364
[TBL] [Abstract][Full Text] [Related]
10. Patient-Derived Tumor Xenografts Plus Ex Vivo Models Enable Drug Validation for Tenosynovial Giant Cell Tumors.
Tang F; Tie Y; Hong WQ; He X; Min L; Zhou Y; Luo Y; Chen SY; Yang JY; Shi HH; Wei XW; Tu CQ
Ann Surg Oncol; 2021 Oct; 28(11):6453-6463. PubMed ID: 33748895
[TBL] [Abstract][Full Text] [Related]
11. Electrophysiology-based stratification of pancreatic tumorigenicity by label-free single-cell impedance cytometry.
McGrath JS; Honrado C; Moore JH; Adair SJ; Varhue WB; Salahi A; Farmehini V; Goudreau BJ; Nagdas S; Blais EM; Bauer TW; Swami NS
Anal Chim Acta; 2020 Mar; 1101():90-98. PubMed ID: 32029124
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer.
Awasthi N; Monahan S; Stefaniak A; Schwarz MA; Schwarz RE
Oncotarget; 2018 Jan; 9(4):5274-5286. PubMed ID: 29435178
[TBL] [Abstract][Full Text] [Related]
13. CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer.
Michaels AD; Newhook TE; Adair SJ; Morioka S; Goudreau BJ; Nagdas S; Mullen MG; Persily JB; Bullock TNJ; Slingluff CL; Ravichandran KS; Parsons JT; Bauer TW
Clin Cancer Res; 2018 Mar; 24(6):1415-1425. PubMed ID: 29288236
[No Abstract] [Full Text] [Related]
14. Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis.
Newhook TE; Lindberg JM; Adair SJ; Kim AJ; Stelow EB; Rahma OE; Parsons JT; Bauer TW
Ann Surg Oncol; 2016 Jun; 23(6):1993-2000. PubMed ID: 26847682
[TBL] [Abstract][Full Text] [Related]
15. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer.
Lindberg JM; Newhook TE; Adair SJ; Walters DM; Kim AJ; Stelow EB; Parsons JT; Bauer TW
Neoplasia; 2014 Jul; 16(7):562-71. PubMed ID: 25117978
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
Awasthi N; Kronenberger D; Stefaniak A; Hassan MS; von Holzen U; Schwarz MA; Schwarz RE
Cancer Lett; 2019 Sep; 459():41-49. PubMed ID: 31153980
[TBL] [Abstract][Full Text] [Related]
17. MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model.
Kawaguchi K; Igarashi K; Miyake K; Lwin TM; Miyake M; Kiyuna T; Hwang HK; Murakami T; Delong JC; Singh SR; Clary B; Bouvet M; Unno M; Hoffman RM
Tissue Cell; 2018 Jun; 52():124-128. PubMed ID: 29857821
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a novel human cell line retaining the characteristics of the original pancreatic adenocarcinoma, and evaluation of MEK as a therapeutic target.
Du X; He K; Huang Y; Xu Z; Kong M; Zhang J; Cao J; Teng L
Int J Oncol; 2020 Mar; 56(3):761-771. PubMed ID: 32124956
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
